Company Monitoring Page for Gilead-Sciences

latest headlines for company on cafepharma

Gilead Sales Chief Retires Amidst Key Hep C Drug Launch, Massive Insider Selling
TheStreet.com
Tue, 01/7/14 - 09:26 am
Tags:
Gilead Sciences, hepatitis C, Sovaldi
22 Biotech Stock Predictions for 2014
TheStreet.com
Mon, 01/6/14 - 09:47 am
Tags:
biotech, Vertex Pharmaceuticals, Orexigen, Retrophin, Valeant Pharmaceuticals, Questcor, Biomarin, Merck, NeoStem, Amgen, Gilead Sciences, Vanda, Keryx, Peregrine Pharmaceuticals, CelSci, Regeneron, Cempra, Dendreon, Clovis Oncology, Halozyme, NPS Pharmaceuticals
Pharmacyclics: As Imbruvica Commercialization Begins, Sell-Off Creates Opportunity
Seeking Alpha
Fri, 01/3/14 - 11:56 am
Tags:
Pharmacyclics, Imbruvica, JNJ, Roche, Celgene, Gilead Sciences, mantle cell lymphoma
Gilead Seeks To Expand Its Blockbuster Hepatitis Platforms In 2014
Seeking Alpha
Fri, 01/3/14 - 11:41 am
Tags:
Gilead Sciences, hepatitis C, Merck, Sovaldi, Vertex
Gilead Sciences: Sovaldi to Boost Shares in 2014, Maxim Group Says
Barron's
Thu, 01/2/14 - 11:28 am
Tags:
Sovaldi, hepatitis C, Gilead Sciences
Grading Pharma In 2013: 16 Drug Companies Ranked
Forbes
Tue, 12/31/13 - 10:17 am
Tags:
Bristol-Myers Squibb, Celgene, Gilead Sciences, Biogen Idec, AbbVie, Roche, JNJ, GSK, Amgen, Novo Nordisk, Pfizer, Novartis, Merck, Sanofi, AstraZeneca, Eli Lilly
Keep an Eye on These 3 Revolutionary Cancer Treatments in 2014
Motley Fool
Fri, 12/27/13 - 01:08 pm
Tags:
cancer, Roche, Infinity Pharmaceuticals, Inovio, Immunogen, Gilead Sciences, immunotherapy, antibody-drug conjugate
Jim Cramer: Ride the Four Horsemen of Biotech
TheStreet.com
Fri, 12/27/13 - 09:34 am
Tags:
biotech, Biogen Idec, Celgene, Gilead Sciences, Regeneron
This Week in Biotech
Motley Fool
Sun, 12/22/13 - 12:28 pm
Tags:
GSK, Theravance, Ariad Pharmaceuticals, Gilead Sciences, AbbVie, Cubist Pharmaceuticals, Jazz Pharmaceuticals, Gentium
2 Big Biotechs Moving Up On News
Seeking Alpha
Fri, 12/20/13 - 12:58 pm
Tags:
Jazz Pharmaceuticals, Gilead Sciences
Why Enanta Pharmaceuticals Shares Sank Like a Stone
Motley Fool
Thu, 12/19/13 - 08:08 am
Tags:
Enanta, Sovaldi, Gilead Sciences, hepatitis C, ABT-450, AbbVie
Gilead to seek okay for combo hepatitis C pill in Q1
Reuters
Wed, 12/18/13 - 10:15 am
Tags:
hepatitis C, Gilead Sciences, Sovaldi, ledipasvir
Ziopharm: Finally A Winner In The War On Cancer?
Seeking Alpha
Mon, 12/16/13 - 08:06 am
Tags:
Ziopharm, cancer, AbbVie, Amgen, Celgene, Celldex Therapeutics, Gilead Sciences, Immunogen, JNJ, ImmunoCellular Therapeutics, Pharmacyclics, Intrexon, Seattle Genetics
Don't Short Gilead Sciences Just Yet
Seeking Alpha
Sat, 12/14/13 - 11:58 am
Tags:
Gilead Sciences
Gilead Sciences' $1,000 Per Day Sovaldi Pills Ready to Launch
Motley Fool
Fri, 12/13/13 - 12:35 pm
Tags:
Gilead Sciences, Sovaldi, drug launches, hepatitis C
Why Talk Of A Hepatitis C Price War Should Act As A Warning To The Pharma Industry-At-Large
Forbes
Wed, 12/11/13 - 08:34 am
Tags:
hepatitis C, drug pricing, Gilead Sciences, Express Scripts
The Numbers Backing Gilead's Best and Fastest Drug Launch in History
TheStreet.com
Mon, 12/9/13 - 08:48 am
Tags:
Gilead Sciences, drug launches, Sovaldi, hepatitis C
New Leukemia Drugs Bring Chemotherapy-Free Treatment Potential
Bloomberg
Mon, 12/9/13 - 08:38 am
Tags:
Gilead Sciences, Roche, Pharmacyclics, CLL, chronic lymphocytic leukemia
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia
Yahoo/BusinessWire
Sun, 12/8/13 - 12:03 pm
Tags:
chronic lymphocytic leukemia, GS-9973, Gilead Sciences
What Everybody Ought to Know About Gilead and Johnson & Johnson's New Hepatitis C Drugs
Seeking Alpha
Fri, 12/6/13 - 10:30 am
Tags:
JNJ, Gilead Sciences, hepatitis C, sofosbuvir, Olysio, AbbVie, Bristol-Myers Squibb, Merck

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.